Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2465445 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Marcello Vaccaro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Unit, Pharmacy Department, Policlinico Umberto I, Rome, Italy. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Practice Patterns, Physicians', Drug Utilization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing. RESEARCH DESIGN AND METHODS: A study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022. RESULTS: The analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I. CONCLUSIONS: A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Unit, Pharmacy Department, Policlinico Umberto I, Rome, Italy.
- Pharmacy Unit, ASL Latina, Latina, Italy.
- Pharmaceutical department, Asl Napoli 3 Sud, Naples, Italy.
- Italian Society of Hospital Pharmacy (SIFO), SIFO Secretariat of the Lombardy Region, Milan, Italy.
- Asl Napoli 3 Sud, Nola, Naples, Italy.
- School of Pharmacy, Università di Camerino, Camerino, Italy.
ORCID-Profile: Andrea Zovi
Zitieren
APA
Vaccaro, M., Polito, G., Bagaglini, G., Capuozzo, M., Langella, R., Nava, E., Zovi, A., & Ferrara, F. (2025). Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2465445
Vancouver
Vaccaro M, Polito G, Bagaglini G, Capuozzo M, Langella R, Nava E, et al. Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2465445
BibTeX
@article{Vaccaro2025,
author = {Vaccaro, Marcello and Polito, Giacomo and Bagaglini, Gabriele and Capuozzo, Maurizio and Langella, Roberto and Nava, Eduardo and Zovi, Andrea and Ferrara, Francesco},
title = {Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2465445}
}
EUVIMED